Alicia McElhaney

Recent Articles By The Author

Express Scripts Falls on Attack From Andrew Left

Express Scripts Falls on Attack From Andrew Left

The comparison to the New York mob boss was only the beginning of Citron Research's inflammatory comments

Abbvie Shares Fall on Mixed Earnings Report

Abbvie Shares Fall on Mixed Earnings Report

The biotech saw shares fall 2.3% after reporting in-line earnings and worse-than-expected revenue.

Immunomedics Shares Ride Roller Coaster on Whether It's for Sale

Immunomedics Shares Ride Roller Coaster on Whether It's for Sale

The company is rumored to be up for sale.

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

McKesson, Bristol-Myers and Varian were having a busy morning.

Johnson & Johnson to Buy Actelion for $30 Billion, Spin Out R&D Unit

Johnson & Johnson to Buy Actelion for $30 Billion, Spin Out R&D Unit

Johnson & Johnson will purchase Swiss biotech Actelion Pharmaceuticals for $30 billion, and it plans to spin out the company's research and development unit into a separate business.

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs' shares fell nearly 1% in premarket trading after the company reported mixed earnings results.

Johnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed Earnings

Johnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed Earnings

CEO Alex Gorsky dishes on Monday's meeting with President Trump during Johnson & Johnson's conference call.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.

Rite Aid Takes a Beating After Report of Walgreens Deal Fears

Rite Aid Takes a Beating After Report of Walgreens Deal Fears

Rite Aid shares fell in dramatic fashion on Friday.